Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quanterix Corporation (NASDAQ: QTRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI‑supported context to help interpret them. As a life sciences and testing laboratories company focused on ultra-sensitive biomarker detection and spatial biology, Quanterix uses its SEC reports to describe its financial performance, corporate transactions, and governance decisions.
Key documents available here include Form 10‑K annual reports and Form 10‑Q quarterly reports, which outline revenue from product sales, service and other revenue, collaboration and license revenue, and grant revenue. These filings also discuss cost of goods sold, research and development expenses, selling, general and administrative expenses, and the use of non‑GAAP measures such as adjusted EBITDA, adjusted gross margin, and adjusted cash usage. AI summaries can highlight how these metrics relate to Quanterix’s Simoa platforms, Accelerator Laboratory services, and the integration of Akoya Biosciences.
Frequent Form 8‑K current reports document material events. Recent examples include announcements of quarterly financial results, the completion and pro forma impact of the Akoya acquisition, shareholder votes on declassifying the Board and eliminating supermajority voting requirements, and changes in Board composition. Our tools surface the main points of each 8‑K so readers can quickly understand what changed and why it matters for QTRX.
Investors can also review proxy statements referenced in the filings for details on director elections, executive compensation proposals, and governance changes, as well as any Form 4 insider transaction reports that may be filed separately. Real‑time updates from EDGAR ensure that new filings appear promptly, while AI‑generated explanations help translate technical accounting and legal language into more accessible summaries.
Use this page to explore Quanterix’s historical and current SEC filings, compare reporting periods, and understand how financial results, acquisitions, and governance actions are reflected in official disclosures.
Ameriprise Financial, Inc. filed an Amendment No. 6 to a Schedule 13G/A reporting shared voting and dispositive power over 990,224 shares of Quanterix Corp common stock, representing 2.1% of the class. The filing lists Quanterix's principal executive office at 900 Middlesex Turnpike, Billerica, MA and states that AFI disclaims beneficial ownership of the reported shares.
Quanterix Corporation reported higher revenue but a mixed bottom line for the quarter ended March 31, 2026. Total revenue rose to $36.4 million from $30.3 million, driven by the 2025 acquisition of Akoya Biosciences, which contributed $8.7 million of product revenue and $3.7 million of service revenue. Legacy Quanterix product revenue fell as U.S. federal research funding cuts and macro-economic pressures reduced consumables demand and Accelerator Laboratory volumes.
Gross profit increased slightly to $15.6 million, but the gross margin declined to 43%, and the operating loss widened to $41.4 million due to a $19.3 million impairment of in‑process R&D tied to a terminated Akoya diagnostic development agreement. That termination also generated $21.6 million of one-time other income. Net loss improved to $17.5 million, or $0.37 per share. Quanterix ended the quarter with $36.2 million in cash and cash equivalents and $63.1 million in marketable securities and continues to target cash flow breakeven in the second half of 2026 while advancing its Alzheimer’s diagnostics strategy, including a 510(k) submission for a multi‑analyte blood test and Medicare pricing of $897 for its LucentAD Complete test.
Quanterix Corporation reported first-quarter 2026 revenue of $36.4 million, up 20% from $30.3 million a year earlier, driven by product and service growth across its Simoa and spatial biology platforms. GAAP gross margin was 42.7%, while adjusted gross margin improved to 50.9% from 49.7%.
The company posted a GAAP net loss of $17.5 million (or $0.37 per share), modestly better than the $20.5 million loss in 2025, and an adjusted EBITDA loss of $9.8 million versus $11.3 million. Quanterix ended the quarter with $102.6 million in cash, cash equivalents, marketable securities and restricted cash.
Management highlighted progress on integrating Akoya Biosciences, citing $85 million of cost synergies realized and a terminated off-market diagnostics contract that drove significant one-time charges and income. The Alzheimer’s diagnostics franchise continues to expand, with several clinical utility studies expected to complete and an FDA decision on a 510(k) application anticipated in the second half of 2026.
For full-year 2026, Quanterix reaffirmed revenue guidance of $169–$174 million, GAAP gross margin of 41–45% and adjusted gross margin of 49–53%. The company continues to expect cash flow breakeven in the second half of 2026 and to finish the year with roughly $100 million in cash and no debt.
Quanterix Corp Chief Operating Officer Michael Francis Miller reported routine equity compensation activity. He exercised 130 restricted stock units that converted into 130 shares of common stock on a one-for-one basis. To cover tax obligations, 39 common shares were disposed of through a tax-withholding transaction, not an open-market sale.
Following these transactions, Miller directly holds 32,613 shares of common stock and 549 restricted stock units that remain outstanding from a prior grant of 6,278 RSUs made on September 23, 2022.
Quanterix Corporation is holding its 2026 annual stockholder meeting virtually at 10:00 a.m. ET on June 9, 2026 via meetnow.global/QTRX2026. Holders of common stock as of April 14, 2026, when 47,064,988 shares were outstanding, may vote.
Stockholders will vote on electing two directors to one-year terms, an advisory approval of named executive officer compensation, an advisory ratification of KPMG LLP as independent auditor for 2026, and approval of an amended and restated 2017 Employee, Director and Consultant Equity Incentive Plan, plus any other properly presented business.
Quanterix Corp Chief Operating Officer Michael Francis Miller exercised restricted stock units into common stock and had shares withheld to cover taxes. On April 15, 2026, he acquired a total of 1,558 shares of common stock through multiple RSU conversions, all at a stated price of $0.00 per share.
To satisfy tax obligations related to these vesting events, 467 shares of common stock were disposed of at $3.60 per share in tax-withholding transactions. Following these transactions, Miller directly held 32,522 shares of Quanterix common stock.
Quanterix Corp Chief Financial Officer Sriram Vandana reported routine equity compensation activity involving restricted stock units that converted into common stock. On April 15, 2026, restricted stock units converted into common stock on a one-for-one basis, delivering 263, 514 and 1,056 shares in separate tranches.
Related common stock entries show 263, 514 and 1,056-share acquisitions at a price of $0.00 per share. To satisfy tax obligations, 79, 154 and 315 shares of common stock were withheld at $3.60 per share as tax-withholding dispositions, rather than open-market sales.
Following these transactions, the filing shows Sriram Vandana directly holding 28,713 shares of Quanterix common stock. The derivative section lists no remaining restricted stock units tied to these specific conversions, underscoring that the reported activity reflects compensation vesting and associated tax withholding.
DONNELLY WILLIAM P reported acquisition or exercise transactions in this Form 4 filing.
Quanterix Corp Executive Chair William P. Donnelly received 6,178 shares of Common Stock as a stock grant. The shares were awarded at a stated price of $0.00 per share as a grant or award transaction, rather than an open-market purchase or sale.
According to the disclosure, this stock was granted in lieu of cash fees for Donnelly’s service on Quanterix’s Board of Directors and its committees for the first quarter of 2026. Following this award, Donnelly directly holds a total of 154,127 shares of Quanterix Common Stock.
Mendel Scott reported acquisition or exercise transactions in this Form 4 filing.
Quanterix Corp director Scott Mendel received a grant of 4,310 shares of common stock as compensation. The shares were granted in lieu of cash fees for his service on the company’s Board of Directors and its committees for the first quarter of 2026. Following this award, he directly holds 12,527 shares.